Novo Nordisk, a Danish drugmaker, has launched its weekly basal insulin injection, Awiqli, in India. Awiqli is prescribed for the treatment of type 1 and type 2 diabetes in adults.
Diabetes Burden in India
More than 101 million people in India are living with diabetes, while another 136 million have prediabetes. Insulin initiation in India is often delayed due to fear of injections, anticipated pain, and cost concerns.
Awiqli is designed to provide background insulin support throughout the week, reducing the number of injections from 365 per year to 52. The drug is expected to compete with other basal insulin brands in India.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.